Neurology/CNS Approved Deal Benchmarks — Europe (2026)
Median upfront of $369M with total deal values reaching $1.3B in Europe territory.
Median Upfront
$369M
Total Deal Value
$1.1B
Royalty Range
11.4%–17.9%
Territory Multiplier
0.25x
Understanding Neurology/CNS Deal Benchmarks at Approved
Approved Neurology/CNS licensing deals in Europe territory command a median upfront payment of $369M, with values ranging from $265M at the low end to $447M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the neurology/cns therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $935M to $1.3B, with a median of $1.1B. Royalty rates for neurology/cns assets at this stage typically fall between 11.4% and 17.9% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The Europe territory applies a 0.25x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating europe rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $265M | $369M | $447M |
| Total Deal Value | $935M | $1.1B | $1.3B |
| Royalty Rate | 11.4% | — | 17.9% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2023 | Takeda | Lundbeck | $100M | $800M | licensing |
| 2021 | Biohaven Pharmaceutical | Pfizer | $500M | $1.2B | licensing |
| 2023 | Eli Lilly | Organon | $50M | $220M | licensing |
| 2024 | Idorsia | Viatris | $0M | $350M | licensing |
See All Comparable Deals
View 4 comparable Neurology/CNS transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Approved Neurology/CNS deals in Europe territory?
How does Europe territory affect Neurology/CNS deal value?
What royalty rates are typical for Approved Neurology/CNS licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$8M upfront
Neurology/CNS · Preclinical · Europe
$19M upfront
Neurology/CNS · Phase 1 · Europe
$58M upfront
Neurology/CNS · Phase 2 · Europe
$129M upfront
Neurology/CNS · Phase 3 · Europe
$519M upfront
Oncology · Approved · Europe
$854M upfront
Immunology · Approved · Europe
$871M upfront
Metabolic/Obesity · Approved · Europe
$1.5B upfront
Neurology/CNS · Approved · Global
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Neurology/CNS Approved Deal Benchmarks — Europe (2026). Retrieved from https://solidus.ambrosiaventures.co/data/neurology-approved-deals-europe
<a href="https://solidus.ambrosiaventures.co/data/neurology-approved-deals-europe">Neurology/CNS Approved Deal Benchmarks — Europe (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=neurology&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.